참고문헌
- Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al. The preclinical pharmacology of roflumilast: a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010;23:235-56. https://doi.org/10.1016/j.pupt.2010.03.011
- Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71. https://doi.org/10.1016/S0140-6736(05)67100-0
- Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61. https://doi.org/10.1164/rccm.200610-1563OC
- Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94. https://doi.org/10.1016/S0140-6736(09)61255-1
- Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, et al. Roflumilast in moderate-tosevere chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703. https://doi.org/10.1016/S0140-6736(09)61252-6
- Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18. https://doi.org/10.1186/1465-9921-12-18
- Lee SD, Hui DS, Mahayiddin AA, Roa CC Jr, Kwa KH, Goehring UM, et al. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology 2011;16:1249-57. https://doi.org/10.1111/j.1440-1843.2011.02038.x
- O'Donnell DE, Bredenbroker D, Brose M, Webb KA. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J 2012;39:1104-12. https://doi.org/10.1183/09031936.00096511
- Zheng J, Yang J, Zhou X, Zhao L, Hui F, Wang H, et al. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest 2014;145:44-52. https://doi.org/10.1378/chest.13-1252
- Michalski JM, Golden G, Ikari J, Rennard SI. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther 2012;91:134-42. https://doi.org/10.1038/clpt.2011.266
- Munoz-Esquerre M, Diez-Ferrer M, Monton C, Pomares X, Lopez-Sanchez M, Huertas D, et al. Roflumilast added to triple therapy in patients with severe COPD: a real life study. Pulm Pharmacol Ther 2015;30:16-21. https://doi.org/10.1016/j.pupt.2014.10.002
- Hwang H, Shin JY, Park KR, Shin JO, Song KH, Park J, et al. Effect of a dose-escalation regimen for improving adherence to Roflumilast in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis 2015;78:321-5. https://doi.org/10.4046/trd.2015.78.4.321
- Rogliani P, Calzetta L, Cazzola M, Matera MG. Drug safety evaluation of roflumilast for the treatment of COPD: a metaanalysis. Expert Opin Drug Saf 2016;15:1133-46. https://doi.org/10.1080/14740338.2016.1199683
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. https://doi.org/10.1183/09031936.05.00034805
- Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol 2017;53:128-49.
- Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-5. https://doi.org/10.1006/pupt.1999.0181
- Lahu G, Facius A. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability. Int J Clin Pharmacol Ther 2013;51:832-6. https://doi.org/10.5414/CP201906
- Park TS, Lee JS, Seo JB, Hong Y, Yoo JW, Kang BJ, et al. Study design and outcomes of Korean Obstructive Lung Disease (KOLD) Cohort Study. Tuberc Respir Dis 2014;76:169-74. https://doi.org/10.4046/trd.2014.76.4.169
- Lee JY, Chon GR, Rhee CK, Kim DK, Yoon HK, Lee JH, et al. Characteristics of patients with chronic obstructive pulmonary disease at the first visit to a pulmonary medical center in Korea: The KOrea COpd Subgroup Study Team Cohort. J Korean Med Sci 2016;31:553-60. https://doi.org/10.3346/jkms.2016.31.4.553
피인용 문헌
- Roflumilast : Headache, insomnia and tremor: 3 case reports vol.1732, pp.1, 2018, https://doi.org/10.1007/s40278-018-55766-3
- Management of COPD in Asia: A position statement of the Asian Pacific Society of Respirology vol.24, pp.10, 2018, https://doi.org/10.1111/resp.13633
- Spanish clinical practice consensus in internal medicine on chronic obstructive pulmonary disease patients with comorbidities (miEPOC) vol.36, pp.6, 2020, https://doi.org/10.1080/03007995.2020.1749995
- Implications of Managing Chronic Obstructive Pulmonary Disease in Cardiovascular Diseases vol.84, pp.1, 2018, https://doi.org/10.4046/trd.2020.0088
- Roflumilast Ameliorates Isoflurane-Induced Inflammation in Astrocytes via the CREB/BDNF Signaling Pathway vol.6, pp.6, 2018, https://doi.org/10.1021/acsomega.0c04799
- Updated view on the treatment of chronic obstructive pulmonary disease in Korea vol.64, pp.3, 2018, https://doi.org/10.5124/jkma.2021.64.3.225